Search Options Stock News and Analysis from Schaeffer's

Why Acadia Pharmaceuticals Stock's Rally Could Have Legs

https://www.schaeffersresearch.com/content/analysis/2022/10/04/why-this-biotech-stocks-rally-could-have-legs

10/4/2022 2:19 PM

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is up 3.3% to trade at $17.60 at last check, as the broader market looks to extend its early October rally. The shares are eyeing their third-straight...

Biotech Stock Plummets After FDA Snub

https://www.schaeffersresearch.com/content/news/2022/06/21/biotech-stock-plummets-after-fda-snub

6/21/2022 10:30 AM

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock is one of the worst stocks on the Nasdaq today, down 35.6% to trade at $12.56 at last check. On Friday, the U.S. Food and Drug Administration (FDA) advi...

ACAD Rises on Acquisition, Initiated Coverage

https://www.schaeffersresearch.com/content/news/2020/08/25/acad-rises-on-acquisition-initiated-coverage

8/25/2020 10:38 AM

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is up 1.15% to trade at $38.40 at last check, after announcing its acquisition of CerSci Therapeutics. The deal will further Acadia's non-opioid pain therapies...

Analysts React to ACADIA Trial Update

https://www.schaeffersresearch.com/content/news/2019/11/26/analysts-react-to-acadia-trial-update

11/26/2019 9:32 AM

It's been a huge year for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), thanks to positive updates for its drugs Nuplazid and pimavanserin, the latter of which again has the pharma name in focus. The ...

Options Hot as ACADIA Pharmaceuticals Stock Soars

https://www.schaeffersresearch.com/content/options/2019/09/09/options-hot-as-acadia-pharmaceuticals-stock-soars

9/9/2019 10:26 AM

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced positive late-stage data for its drug pimavanserin in patents suffering from dementia-related psychosis. The San Diego-based biopharmaceutical firm ...

PEOPLE ALSO SEARCH FOR